A minimal region of the HSP90AB1 promoter is suitable for ubiquitous expression in different somatic tissues with applicability for gene therapy
- Michal Mielcarek, Mark Isalan, Michal Mielcarek, Mark Isalan
- None, 10.3389/fmolb.2023.1175407
A primer to directed evolution: current methodologies and future directions
- Lara Sellés Vidal, Mark Isalan, John T Heap, Rodrigo Ledesma-Amaro
- None, 10.1039/d2cb00231k
Emergent expression of fitness-conferring genes by phenotypic selection
- Marta Ciechonska, Marc Sturrock, Alice Grob, …, Gerald Larrouy-Maumus, Vahid Shahrezaei, Mark Isalan
- None, 10.1093/pnasnexus/pgac069
Identification of the Transcriptional Biomarkers Panel Linked to Pathological Remodelling of the Eye Tissues in Various HD Mouse Models
- Iwona Mazur-MichaÅ‚ek, Marcin RuciÅ„ski, Mateusz SowiÅ„ski, …, Witold Szaflarski, Mark Isalan, Michal Mielcarek
- Cells, 10.3390/cells11101675
A genetic toolkit and gene switches to limit Mycoplasma growth for biosafety applications
- Alicia Broto, Erika Gaspari, Samuel Miravet-Verde, Vitor A P Martins Dos Santos, Mark Isalan
- Nat Commun, 10.1038/s41467-022-29574-0
Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings
- Hau Kiu Edna Au, Mark Isalan, Michal Mielcarek
- None, 10.3389/fmed.2021.809118
Synthetic spatial patterning in bacteria: advances based on novel diffusible signals
- Martina Oliver Huidobro, Jure Tica, Georg K A Wachter, Mark Isalan
- Microb Biotechnol, 10.1111/1751-7915.13979
The Application of CRISPR/Cas Systems for Antiviral Therapy
- Helen J E Baddeley, Mark Isalan
- None, 10.3389/fgeed.2021.745559
Kinetin stimulates differentiation of C2C12 myoblasts
- Michal Mielcarek, Mark Isalan
- PLoS One, 10.1371/journal.pone.0258419
Polyglutamine diseases: looking beyond the neurodegenerative universe
- Michal Mielcarek, Mark Isalan
- None, 10.4103/1673-5374.300434